![High-Investment-Medications Predictability Affordability and Accessibility Report - Cover](https://amcp.org/sites/default/files/styles/card_fullsize/public/images/High-Investment-Medications-Predictability-Affordability-and-Accessibility-1humb.png.webp?itok=RzqtatoR)
The FDA continues to approve novel therapies, but concerns arise due to the costs of certain treatments. To address this, the AMCP organized a forum to explore solutions. Stakeholders recognize the benefits of high-investment medications, but uptake of payment strategies has been slow. Gradual changes, education, and collaboration are essential to improve predictability, affordability, and accessibility for patients.